Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

NCT04119024 is registered in ClinicalTrials.gov with Anusha Kalbasi as lead sponsor.

NCT NCT04119024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04119024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Lead sponsor
Anusha Kalbasi
Phase
Phase 1
Overall status
Recruiting
Start date
October 7, 2025
Completion date
October 31, 2026
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acral melanoma, adrenocortical carcinoma, breast cancer, head and neck squamous cell carcinoma, lung adenocarcinoma, metastatic malignant solid neoplasm, metastatic melanoma, neuroendocrine tumors, pancreatic neuroendocrine tumor, paraganglioma, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, pheochromocytoma, recurrent malignant solid neoplasm, refractory malignant solid neoplasm, thyroid cancer, uveal melanoma